Literature DB >> 26794233

Direct comparison of clinical decision limits for cardiac troponin T and I.

Dorien M Kimenai1, Ronald M A Henry2, Carla J H van der Kallen2, Pieter C Dagnelie3, Miranda T Schram2, Coen D A Stehouwer4, Jeroen D E van Suijlen5, Marijke Niens5, Otto Bekers1, Simone J S Sep2, Nicolaas C Schaper4, Marja P van Dieijen-Visser1, Steven J R Meex1.   

Abstract

OBJECTIVE: The 99th percentile upper reference limit of high-sensitivity cardiac troponin (hs-cTn) from a healthy reference population is used for diagnosing acute myocardial infarction (AMI). Accepted current thresholds of hs-cTnT (Roche) and hs-cTnI (Abbott) are 14 and 26 ng/L, respectively. Since thresholds for hs-cTnT and hs-cTnI were derived from different reference cohorts it is unclear whether they are biologically equivalent. We directly assessed sex-specific and age-specific 99th percentile upper reference limits of hs-cTnT and hs-cTnI in a single reference cohort, to investigate whether current divergent thresholds of hs-cTnT and hs-cTnI stem from intrinsic assay differences or reflect cohort variation.
METHODS: A healthy reference population was derived from a population-based cohort (the Maastricht Study: n=3451; age: 40-75 years). Individuals with diabetes mellitus, a history of cardiovascular disease, cardiac ischaemia on ECG, N-terminal pro-brain natriuretic peptide >125 ng/L or estimated glomerular filtration rate <60 mL/min/1.73 m(2) were excluded. Non-parametric analyses were performed to assess 99th percentile upper reference limits.
RESULTS: 1540 individuals were included in the healthy reference population (age 57±8 years, 52.4% women). Overall 99th percentile upper reference limits of hs-cTnT and hs-cTnI were 15 and 13 ng/L, respectively. Upper reference limits were higher in men than women (hs-cTnT: 16 vs 12 ng/L), (hs-cTnI: 20 vs 11 ng/L) and increased with age.
CONCLUSIONS: Direct comparison reveals numerically similar thresholds for hs-cTnT and hs-cTnI assays. This finding is in line with recently reported underdiagnosis of AMI with the current decision limit of 26 ng/L for hs-cTnI, especially among women. Downwards adjustment of the hs-cTnI threshold, differentiated for sex, would equalise clinical decision limits for both assays, and may prevent further underdiagnosis of AMI. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26794233     DOI: 10.1136/heartjnl-2015-308917

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  16 in total

1.  High-sensitivity detection of cardiac troponin I with UV LED excitation for use in point-of-care immunoassay.

Authors:  Olga Rodenko; Susann Eriksson; Peter Tidemand-Lichtenberg; Carl Peder Troldborg; Henrik Fodgaard; Sylvana van Os; Christian Pedersen
Journal:  Biomed Opt Express       Date:  2017-07-20       Impact factor: 3.732

2.  Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort.

Authors:  Paul Welsh; David Preiss; Anoop S V Shah; David McAllister; Andrew Briggs; Charles Boachie; Alex McConnachie; Caroline Hayward; Sandosh Padmanabhan; Claire Welsh; Mark Woodward; Archie Campbell; David Porteous; Nicholas L Mills; Naveed Sattar
Journal:  Clin Chem       Date:  2018-08-20       Impact factor: 8.327

3.  Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation.

Authors:  Yader Sandoval; Bradley R Lewis; Ramila A Mehta; Olatunde Ola; Jonathan D Knott; Laura De Michieli; Ashok Akula; Ronstan Lobo; Eric H Yang; S Michael Gharacholou; Marshall Dworak; Erika Crockford; Nicholas Rastas; Eric Grube; Swetha Karturi; Scott Wohlrab; David O Hodge; Tahir Tak; Charles Cagin; Rajiv Gulati; Allan S Jaffe
Journal:  Circulation       Date:  2022-05-10       Impact factor: 39.918

4.  Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes.

Authors:  Júlia Karády; Thomas Mayrhofer; Maros Ferencik; John T Nagurney; James E Udelson; Andreas A Kammerlander; Jerome L Fleg; W Frank Peacock; James L Januzzi; Wolfgang Koenig; Udo Hoffmann
Journal:  J Am Coll Cardiol       Date:  2021-03-30       Impact factor: 24.094

5.  The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure.

Authors:  Biyanka Jaltotage; Girish Dwivedi; Daryl Eng Lee Ooi; Gnanadevan Mahadavan
Journal:  Curr Cardiol Rev       Date:  2021

6.  Comparing Methods for Measurement Error Detection in Serial 24-h Hormonal Data.

Authors:  Evie van der Spoel; Jungyeon Choi; Ferdinand Roelfsema; Saskia le Cessie; Diana van Heemst; Olaf M Dekkers
Journal:  J Biol Rhythms       Date:  2019-06-12       Impact factor: 3.182

Review 7.  Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More?

Authors:  Giulio Francesco Romiti; Roberto Cangemi; Filippo Toriello; Eleonora Ruscio; Susanna Sciomer; Federica Moscucci; Marianna Vincenti; Clara Crescioli; Marco Proietti; Stefania Basili; Valeria Raparelli
Journal:  Cardiovasc Ther       Date:  2019-02-05       Impact factor: 3.023

8.  Determination of high-sensitivity cardiac troponin T upper reference limits under the improved selection criteria in a Chinese population.

Authors:  Xin Zhang; Xiaoxu Han; Min Zhao; Runqing Mu; Shuo Wang; Ke Yun; Hong Shang
Journal:  J Clin Lab Anal       Date:  2019-08-16       Impact factor: 2.352

Review 9.  Volatile sedation in the intensive care unit: A systematic review and meta-analysis.

Authors:  Ha Yeon Kim; Ja Eun Lee; Ha Yan Kim; Jeongmin Kim
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 10.  Highly Sensitive Cardiac Troponins: The Evidence Behind Sex-Specific Cutoffs.

Authors:  Prerana M Bhatia; Lori B Daniels
Journal:  J Am Heart Assoc       Date:  2020-05-09       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.